Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Kyntra Bio Inc (KYNB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.66-7.58%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KYNB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Successful clinical trial results for roxadustat MDS | Positive trial data supports future products. | Intact | trial data turns negative or fails to advance | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, development-stage healthcare business, not a proven earnings compounder. Its long-term thesis is still in a watch state: trial work is progressing, but recent financial performance is weak and the risk label has risen to high.
KYNB is described as cheap versus peers, with the valuation model showing a large negative expectations gap, meaning expectations appear low relative to the model’s benchmark. The pricing signal is marked justified, with no fragility gates triggered, but confidence is medium and the evidence does not show exactly what investors assume.
Near term, the elevated risk of an earnings miss and weak performance versus the industry cohort make results and guidance important. Management has kept the FG-3246 Phase 2 trial on track, while the roxadustat Phase 3 timeline is mixed; reported liquidity is expected to fund operations into 2028. A delisting-rule notice is also a recent negative event, while the details and implications are not provided here.
The multi-year view depends on execution in the two clinical programs and on maintaining the stated cash runway. Near term, a guidance cut or further labor-market weakness would add pressure, while continued strong results and guidance from healthcare bellwethers could support the sector backdrop.
Over the next 1 to 3 years, KYNB remains a high-risk clinical-development story with some trial progress and a stated runway into 2028, but weak performance and event risk keep the thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management is working to reduce losses. |
| Intact |
| operating losses worsen beyond -$13.8 million quarterly |
Operating income: $-17.574M FY2026-Q2; GAAP. Published target: operating losses improve from -$13.8 million quarterly. Target period is not explicitly aligned with this observation. Aug 13, 2026-17,574,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Grow revenue above $3.7M quarterly | A primary condition in Kyntra Bio Inc's published investment case. The stated target is >=$3.7 million quarterly revenue. | Broken | quarterly revenue falls below $3.7 million | Revenue: $-1.474M FY2026-Q2; GAAP. Published target: >=$3.7 million quarterly revenue. Target period is not explicitly aligned with this observation. Aug 13, 2026-1,474,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-11.44 → $-9.86 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-11.44 | $8,805,633 | 2 / 2 |
| 2026-07-25 | $-11.44 | $8,805,633 | 2 / 2 |
| 2026-07-26 | $-11.44 | $8,805,633 | 2 / 2 |
| 2026-07-27 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-07-28 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-07-29 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-07-30 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-07-31 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-08-01 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-02 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-08-03 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-04 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-08-05 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-08-06 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-07 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-08 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-08-09 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-10 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-12 | $-11.44 | $8,805,670 | 3 / 3 |
| 2026-08-13 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-14 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-15 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-16 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-17 | $-11.44 | $8,805,633 | 3 / 3 |
| 2026-08-18 | $-11.44 | $8,805,633 | 2 / 3 |
| 2026-08-19 | $-11.44 | $8,805,633 | 2 / 3 |
| 2026-08-20 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-21 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-22 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-23 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-24 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-25 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-26 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-27 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-28 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-29 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-30 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-08-31 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-09-01 | $-12.58 | $8,138,999 | 2 / 3 |
| 2026-09-02 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-03 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-04 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-05 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-06 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-07 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-08 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-09 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-10 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-11 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-12 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-13 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-14 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-15 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-16 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-17 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-18 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-19 | $-12.58 | $8,133,333 | 2 / 3 |
| 2026-09-20 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-21 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-22 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-23 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-24 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-25 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-26 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-27 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-28 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-29 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-09-30 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-01 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-02 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-03 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-04 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-05 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-06 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-07 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-08 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-09 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-10 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-11 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-12 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-13 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-14 | $-11.30 | $7,662,500 | 3 / 3 |
| 2026-10-15 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-16 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-17 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-18 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-19 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-20 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-21 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-22 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-23 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-24 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-25 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-26 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-27 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-28 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-29 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-30 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-10-31 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-11-01 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-11-02 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-11-03 | $-9.86 | $7,330,000 | 3 / 4 |
| 2026-11-04 | $-9.86 | $7,330,000 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.